| 7.6 -0.45 (-5.59%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.8 | 1-year : | 12.61 |
| Resists | First : | 9.25 | Second : | 10.8 |
| Pivot price | 8.46 |
|||
| Supports | First : | 7.01  |
Second : | 5.63 |
| MAs | MA(5) : | 8.22 |
MA(20) : | 8.43 |
| MA(100) : | 6.28 |
MA(250) : | 8.98 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 8 |
D(3) : | 23.8 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 12.93 | Low : | 4.94 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LNSR ] has closed below the lower bollinger band by 10.1%. Bollinger Bands are 3.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.2 - 8.25 | 8.25 - 8.28 |
| Low: | 7.49 - 7.55 | 7.55 - 7.6 |
| Close: | 7.52 - 7.61 | 7.61 - 7.68 |
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Wed, 02 Sep 2026
LENSAR Inc (LNSR) Stock News Today - TradingKey
Mon, 24 Aug 2026
Lensar Inc Earnings Call Highlights Growth Momentum - The Globe and Mail
Thu, 20 Aug 2026
LENSAR (LNSR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Thu, 13 Aug 2026
LENSAR, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Wed, 12 Aug 2026
Earnings To Watch: LENSAR Inc (LNSR) Q2 2026 -- GF Value Sees 13% Upside - Yahoo Finance
Wed, 29 Jul 2026
BlackRock, Inc. (LNSR) discloses 184,053-share beneficial stake in LENSAR - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 12 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 21.5 (%) |
| Held by Institutions | 45.9 (%) |
| Shares Short | 415 (K) |
| Shares Short P.Month | 483 (K) |
| EPS | 0.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.21 |
| Profit Margin | 57.5 % |
| Operating Margin | 12.9 % |
| Return on Assets (ttm) | -18.7 % |
| Return on Equity (ttm) | 357.2 % |
| Qtrly Rev. Growth | 18.3 % |
| Gross Profit (p.s.) | 2.37 |
| Sales Per Share | 4.9 |
| EBITDA (p.s.) | -1.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | 38 |
| PEG Ratio | 0 |
| Price to Book value | 6.28 |
| Price to Sales | 1.55 |
| Price to Cash Flow | -12.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|